[Pikamilone treatment of benign prostatic hyperplasia].
Pikamilone is an original drug of Russian produce having a central (vegetotropic and vascular) and peripheral (vasodilating) mechanisms of action. The drug was tried as monotherapy in elderly patients with benign prostatic hyperplasia who had symptoms of the lower urinary tracts to estimate its effect on local and general mechanisms of nervous and vascular regulation of detruzor function in infravesical obstruction. A positive trend in the clinical symptoms was observed (by IPSS scale), especially irritative symptoms. Urodynamics has also improved: maximal and mean urinary flow rate and total amount of urination increased. However, the residual urine volume remained the same. Further placebo-controlled and randomized studies are needed for precise estimation of pikamilone effects. Meanwhile, the drug can be used as a component of combined therapy of benign prostatic hyperplasia.
Tolstova
S S
SS
D000284:Administration, Oral; D000368:Aged; D006801:Humans; D008297:Male; D011379:Prognosis; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000503:physiopathology; D001743:Urinary Bladder / Q000098:blood supply / Q000187:drug effects; D014563:Urodynamics / Q000187:drug effects; D014665:Vasodilator Agents / Q000008:administration & dosage*; D005680:gamma-Aminobutyric Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use*
D014665:Vasodilator Agents; C044905:nicotinoyl-GABA; D005680:gamma-Aminobutyric Acid